Business Context and Reporting Period
This Form 8-K is a current report filed by BioSig Technologies, Inc. (not Streamex Corp.) on January 31, 2024. The filing reports the formal implementation of a reverse stock split previously approved by stockholders at the annual meeting on December 18, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split Execution: The Company filed an amendment to its Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective February 1, 2024, at 4:05 p.m. (New York time).
- Share Count Reduction: The number of outstanding common shares will be reduced from 93,344,435 to approximately 9,334,636.
- Fractional Shares: No fractional shares will be issued; any fractional entitlements will be rounded up to the next whole number.
- Trading Adjustments: Common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on February 2, 2024, under the symbol BSGM with a new CUSIP number (09073N300).
- Derivative Adjustments: Proportionate adjustments will be made to exercise prices and share counts for outstanding stock options, RSUs, warrants, and convertible preferred stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks beyond the standard disclosure regarding the reverse stock split mechanics. The primary purpose is to notify the market of the completed corporate action.
Investor Verification Checklist
- Verify the new CUSIP number (09073N300) for trading purposes starting February 2, 2024.
- Confirm the adjusted number of shares held in brokerage accounts post-split, noting the rounding up of fractional shares.
- Review the impact of the 1-for-10 split on the exercise price and share quantity of any held options, warrants, or convertible securities.
- Note that the authorized share count remains unchanged despite the reduction in outstanding shares.